BMS-986523

Phase 2Small molecule

Bristol-Myers Squibb

BMS-986523 is one of 18 small molecule programs targeting Advanced Solid Malignancies. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Advanced Solid MalignanciesRecruiting

Advanced Solid MalignanciesPhase 2

Recruiting

Competition

Competitive Landscape

28 competitors in Advanced Solid Malignancies

#DrugCompanyPhaseTrials

Keytruda

Merck & Co.

Phase 2

6 2

Abraxane

Bristol-Myers Squibb

Phase 2

2 3

Gemzar

Johnson & Johnson

Phase 2

2 4

Erbitux

IImclone

Phase 2

3 5

Tuoyi

CCoherus Oncology, Inc.

Phase 2

1 6

Tecentriq

Roche

Phase 1

1 7

Yervoy

Bristol-Myers Squibb

Phase 1

1 8

IBI363

Innovent Biologics (Suzhou) Co. Ltd.

Phase 2

1 9

Herceptin

OOrganon and Co

Phase 1

2 10

Tiragolumab

Roche

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Phase 1/2Recruiting

Advanced Solid Malignancies

NCT07223047

Clinical

Trials by Indication[1]

Advanced Solid Malignancies1 trial

A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies

Recruiting· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1/2·NCT07223047·252 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for BMS-986523. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — BMS-986523 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for BMS-986523. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Bristol-Myers Squibb company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Bristol-Myers Squibb

BMS-986523

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Trials by Indication[1]

Advanced Solid Malignancies1 trial

References

Drug Info

Quick Facts

Related News